EBS Quote, Financials, Valuation and Earnings

Editas Medicine has a net margin of -16.54% compared to Emergent BioSolutions's net margin of -148.33%. Emergent BioSolutions's return on equity of -35.42% beat Editas Medicine's return on equity of -100%.

Emergent BioSolutions has a consensus price target of $13.50, signalling upside risk potential of 181.84%. On the other hand Editas Medicine has an analysts' consensus of $3.67 which suggests that it could grow by 175.69%. Given that Emergent BioSolutions has higher upside potential than Editas Medicine, analysts believe Emergent BioSolutions is more attractive than Editas Medicine.

Emergent BioSolutions has a beta of 2.088, which suggesting that the stock is 108.753% more volatile than S&P 500. In comparison Editas Medicine has a beta of 2.149, suggesting its more volatile than the S&P 500 by 114.892%.

Emergent BioSolutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Editas Medicine offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions pays -- of its earnings as a dividend. Editas Medicine pays out -- of its earnings as a dividend.

Emergent BioSolutions quarterly revenues are $189.3M, which are larger than Editas Medicine quarterly revenues of $30.6M. Emergent BioSolutions's net income of -$31.3M is higher than Editas Medicine's net income of -$45.4M. Notably, Emergent BioSolutions's price-to-earnings ratio is -- while Editas Medicine's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions is 0.25x versus 3.39x for Editas Medicine. Usually stocks with elevated PS ratios are considered overvalued.

Ocugen has a net margin of -16.54% compared to Emergent BioSolutions's net margin of -1816.75%. Emergent BioSolutions's return on equity of -35.42% beat Ocugen's return on equity of -171.04%.

Emergent BioSolutions has a consensus price target of $13.50, signalling upside risk potential of 181.84%. On the other hand Ocugen has an analysts' consensus of $6.75 which suggests that it could grow by 843.79%. Given that Ocugen has higher upside potential than Emergent BioSolutions, analysts believe Ocugen is more attractive than Emergent BioSolutions.

Emergent BioSolutions has a beta of 2.088, which suggesting that the stock is 108.753% more volatile than S&P 500. In comparison Ocugen has a beta of 4.214, suggesting its more volatile than the S&P 500 by 321.428%.

Emergent BioSolutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions pays -- of its earnings as a dividend. Ocugen pays out -- of its earnings as a dividend.

Emergent BioSolutions quarterly revenues are $189.3M, which are larger than Ocugen quarterly revenues of $764K. Emergent BioSolutions's net income of -$31.3M is lower than Ocugen's net income of -$13.9M. Notably, Emergent BioSolutions's price-to-earnings ratio is -- while Ocugen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions is 0.25x versus 47.79x for Ocugen. Usually stocks with elevated PS ratios are considered overvalued.

Ocular Therapeutix has a net margin of -16.54% compared to Emergent BioSolutions's net margin of -283.27%. Emergent BioSolutions's return on equity of -35.42% beat Ocular Therapeutix's return on equity of -62.66%.

Emergent BioSolutions has a consensus price target of $13.50, signalling upside risk potential of 181.84%. On the other hand Ocular Therapeutix has an analysts' consensus of $17.50 which suggests that it could grow by 143.9%. Given that Emergent BioSolutions has higher upside potential than Ocular Therapeutix, analysts believe Emergent BioSolutions is more attractive than Ocular Therapeutix.

Emergent BioSolutions has a beta of 2.088, which suggesting that the stock is 108.753% more volatile than S&P 500. In comparison Ocular Therapeutix has a beta of 1.508, suggesting its more volatile than the S&P 500 by 50.759%.

Emergent BioSolutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocular Therapeutix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions pays -- of its earnings as a dividend. Ocular Therapeutix pays out -- of its earnings as a dividend.

Emergent BioSolutions quarterly revenues are $189.3M, which are larger than Ocular Therapeutix quarterly revenues of $17.1M. Emergent BioSolutions's net income of -$31.3M is higher than Ocular Therapeutix's net income of -$48.4M. Notably, Emergent BioSolutions's price-to-earnings ratio is -- while Ocular Therapeutix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions is 0.25x versus 17.82x for Ocular Therapeutix. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of -16.54% compared to Emergent BioSolutions's net margin of 4.19%. Emergent BioSolutions's return on equity of -35.42% beat TG Therapeutics's return on equity of 19.78%.

Emergent BioSolutions has a consensus price target of $13.50, signalling upside risk potential of 181.84%. On the other hand TG Therapeutics has an analysts' consensus of $43.50 which suggests that it could grow by 24.79%. Given that Emergent BioSolutions has higher upside potential than TG Therapeutics, analysts believe Emergent BioSolutions is more attractive than TG Therapeutics.

Emergent BioSolutions has a beta of 2.088, which suggesting that the stock is 108.753% more volatile than S&P 500. In comparison TG Therapeutics has a beta of 2.208, suggesting its more volatile than the S&P 500 by 120.838%.

Emergent BioSolutions has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Emergent BioSolutions pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

Emergent BioSolutions quarterly revenues are $189.3M, which are larger than TG Therapeutics quarterly revenues of $120.9M. Emergent BioSolutions's net income of -$31.3M is lower than TG Therapeutics's net income of $5.1M. Notably, Emergent BioSolutions's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 145.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Emergent BioSolutions is 0.25x versus 14.51x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.